Preclinical studies have suggested that PARP inhibitors and anti-angiogenic therapy may favour response to immune checkpoint blockade in ovarian cancer. Here the authors report efficacy and translational data of a phase II trial of anti-PD-L1 durvalumab and cediranib (anti-angiogenic drug) with and without the PARP inhibitor olaparib in patients with recurrent ovarian cancer.
- Junya Tabata
- Tzu-Ting Huang
- Jung-Min Lee
